Microglial toll-like receptors and Alzheimer's disease

Brain, Behavior, and Immunity

Volumn 52, Issue , 2016, Pages 187-198

  Su, Fan ^a   Bai, Feng ^a   Zhou, Hong ^a   Zhang, Zhijun ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Microglia; Neuroinflammation; Toll like receptors

Indexed keywords

CASPASE 3; CD14 ANTIGEN; CD36 ANTIGEN; FORMYLPEPTIDE RECEPTOR LIKE 1; GELATINASE B; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYTOKINE;

ALZHEIMER DISEASE; CELL ACTIVATION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVATION; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRACELLULAR SIGNALING; MICROGLIA; MOLECULAR PATHOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TLR GENE; UPREGULATION; ANIMAL; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CYTOKINES; HUMANS; MICROGLIA; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTORS;

EID: 84953353921     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.10.010     Document Type: Review

References (161)

1. Aloisi F. Immune function of microglia. Glia 2001, 36:165-179.
2. Anthony S.G., Schipper H.M., Tavares R., Hovanesian V., Cortez S.C., Stopa E.G., Johanson C.E. Stress protein expression in the Alzheimer-diseased choroid plexus. J. Alzheimer's Dis.: JAD 2003, 5:171-177.
3. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000, 25:187-191.
4. Arvanitakis Z., Grodstein F., Bienias J.L., Schneider J.A., Wilson R.S., Kelly J.F., Evans D.A., Bennett D.A. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008, 70:2219-2225.
5. Babcock A.A., Wirenfeldt M., Holm T., Nielsen H.H., Dissing-Olesen L., Toft-Hansen H., Millward J.M., Landmann R., Rivest S., Finsen B., Owens T. Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J. Neurosci. 2006, 26:12826-12837.
6. Bachstetter A.D., Xing B., de Almeida L., Dimayuga E.R., Watterson D.M., Van Eldik L.J. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). J. Neuroinflammation 2011, 8:79.
7. Bai Y., Zhu Z., Gao Z., Kong Y. TLR2 signaling directs NO-dependent MMP-9 induction in mouse microglia. Neurosci. Lett. 2014, 571:5-10.
8. Balistreri C.R., Caruso C., Listi F., Colonna-Romano G., Lio D., Candore G. LPS-mediated production of pro/anti-inflammatory cytokines and eicosanoids in whole blood samples: biological effects of +896A/G TLR4 polymorphism in a Sicilian population of healthy subjects. Mech. Ageing Dev. 2011, 132:86-92.
9. Balistreri C.R., Grimaldi M.P., Chiappelli M., Licastro F., Castiglia L., Listi F., Vasto S., Lio D., Caruso C., Candore G. Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr. Pharm. Des. 2008, 14:2672-2677.
10. Bank S., Skytt Andersen P., Burisch J., Pedersen N., Roug S., Galsgaard J., Ydegaard Turino S., Broder Brodersen J., Rashid S., Kaiser Rasmussen B., Avlund S., Bastholm Olesen T., Jurgen Hoffmann H., Kragh Thomsen M., Ostergaard Thomsen V., Frydenberg M., Andersen Nexo B., Sode J., Vogel U., Andersen V. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS ONE 2014, 9:e98815.
11. Barger S.W., Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881.
12. Bellucci A., Westwood A.J., Ingram E., Casamenti F., Goedert M., Spillantini M.G. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 2004, 165:1643-1652.
13. Bitting L., Naidu A., Cordell B., Murphy G.M. Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. J. Biol. Chem. 1996, 271:16084-16089.
14. Bornemann K.D., Wiederhold K.H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 2001, 158:63-73.
15. Breitner J.C., Haneuse S.J., Walker R., Dublin S., Crane P.K., Gray S.L., Larson E.B. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72:1899-1905.
16. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
17. Butchi N.B., Du M., Peterson K.E. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia. Glia 2010, 58:650-664.
18. Cacabelos R., Barquero M., Garcia P., Alvarez X.A., Varela de Seijas E. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp. Clin. Pharmacol. 1991, 13:455-458.
19. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
20. Calabrese V., Sultana R., Scapagnini G., Guagliano E., Sapienza M., Bella R., Kanski J., Pennisi G., Mancuso C., Stella A.M., Butterfield D.A. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 2006, 8:1975-1986.
21. Capiralla H., Vingtdeux V., Zhao H., Sankowski R., Al-Abed Y., Davies P., Marambaud P. Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. J. Neurochem. 2012, 120:461-472.
22. Chakrabarty P., Li A., Ceballos-Diaz C., Eddy J.A., Funk C.C., Moore B., DiNunno N., Rosario A.M., Cruz P.E., Verbeeck C., Sacino A., Nix S., Janus C., Price N.D., Das P., Golde T.E. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 2015, 85:519-533.
23. Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E.H., Lockett S., Dunlop N.M., Wang J.M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 2006, 281:3651-3659.
24. Chen K., Zhang L., Huang J., Gong W., Dunlop N.M., Wang J.M. Cooperation between NOD2 and Toll-like receptor 2 ligands in the up-regulation of mouse mFPR2, a G-protein-coupled Abeta42 peptide receptor, in microglial cells. J. Leukocyte Biol. 2008, 83:1467-1475.
25. Chen K.H., Zeng L., Gu W., Zhou J., Du D.Y., Jiang J.X. Polymorphisms in the toll-like receptor 9 gene associated with sepsis and multiple organ dysfunction after major blunt trauma. Br. J. Surg. 2011, 98:1252-1259.
26. Chen Y.C., Yip P.K., Huang Y.L., Sun Y., Wen L.L., Chu Y.M., Chen T.F. Sequence variants of toll like receptor 4 and late-onset Alzheimer's disease. PLoS ONE 2012, 7:e50771.
27. Chen Y.J., Hsieh M.Y., Chang M.Y., Chen H.C., Jan M.S., Maa M.C., Leu T.H. Eps8 protein facilitates phagocytosis by increasing TLR4-MyD88 protein interaction in lipopolysaccharide-stimulated macrophages. J. Biol. Chem. 2012, 287:18806-18819.
28. Clark A.K., Staniland A.A., Marchand F., Kaan T.K., McMahon S.B., Malcangio M. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J. Neurosci. 2010, 30:573-582.
29. Colton C., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010, 9:174-191.
30. Costello D.A., Carney D.G., Lynch M.A. Alpha-TLR2 antibody attenuates the Abeta-mediated inflammatory response in microglia through enhanced expression of SIGIRR. Brain Behav. Immun. 2015, 46:70-79.
31. Daniele S.G., Beraud D., Davenport C., Cheng K., Yin H., Maguire-Zeiss K.A. Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal 2015, 8:ra45.
32. David B.T., Ratnayake A., Amarante M.A., Reddy N.P., Dong W., Sampath S., Heary R.F., Elkabes S. A toll-like receptor 9 antagonist reduces pain hypersensitivity and the inflammatory response in spinal cord injury. Neurobiol. Dis. 2013, 54:194-205.
33. Dias I.H., Mistry J., Fell S., Reis A., Spickett C.M., Polidori M.C., Lip G.Y., Griffiths H.R. Oxidized LDL lipids increase beta-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation. Free Radic. Biol. Med. 2014, 75:48-59.
34. Doens D., Fernandez P.L. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J. Neuroinflammation 2014, 11:48.
35. Doi Y., Mizuno T., Maki Y., Jin S., Mizoguchi H., Ikeyama M., Doi M., Michikawa M., Takeuchi H., Suzumura A. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am. J. Pathol. 2009, 175:2121-2132.
36. Doyle S.E., O'Connell R.M., Miranda G.A., Vaidya S.A., Chow E.K., Liu P.T., Suzuki S., Suzuki N., Modlin R.L., Yeh W.C., Lane T.F., Cheng G. Toll-like receptors induce a phagocytic gene program through p38. J. Exp. Med. 2004, 199:81-90.
37. Duan Z.X., Gu W., Zhang L.Y., Du D.Y., Hu P., Huang J., Liu Q., Wang Z.G., Hao J., Jiang J.X. Clinical relevance of the TLR4 11367 polymorphism in patients with major trauma. Arch. Surg. 2009, 144:1144-1148.
38. Duan Z.X., Zhu P.F., Dong H., Gu W., Yang C., Liu Q., Wang Z.G., Jiang J.X. Functional significance of the TLR4/11367 polymorphism identified in Chinese Han population. Shock 2007, 28:160-164.
39. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
40. Figueroa L., Xiong Y., Song C., Piao W., Vogel S.N., Medvedev A.E. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J. Immunol. 2012, 188:4506-4515.
41. Galasko D., Montine T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarker Med. 2010, 4:27-36.
42. Grammas P., Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 2001, 22:837-842.
43. Hamann L., Glaeser C., Hamprecht A., Gross M., Gomma A., Schumann R.R. Toll-like receptor (TLR)-9 promotor polymorphisms and atherosclerosis. Clin. Chim. Acta 2006, 364:303-307.
44. Hamilton R.L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10:378-384.
45. Hanke M.L., Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin. Sci. (London) 2011, 121:367-387.
46. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
47. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:137-143.
48. Honda K., Ohba Y., Yanai H., Negishi H., Mizutani T., Takaoka A., Taya C., Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-1040.
49. Hu F., Ku M.C., Markovic D., a Dzaye O.D., Lehnardt S., Synowitz M., Wolf S.A., Kettenmann H. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int. J. Cancer 2014, 135:2569-2578.
50. Hyakkoku K., Hamanaka J., Tsuruma K., Shimazawa M., Tanaka H., Uematsu S., Akira S., Inagaki N., Nagai H., Hara H. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010, 171:258-267.
51. Iribarren P., Chen K., Hu J., Gong W., Cho E.H., Lockett S., Uranchimeg B., Wang J.M. CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2. FASEB J.: official publication of the Federation of American Societies for Experimental Biology 2005, 19:2032-2034.
52. Jana M., Palencia C.A., Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J. Immunol. 2008, 181:7254-7262.
53. Janelsins M.C., Mastrangelo M.A., Oddo S., LaFerla F.M., Federoff H.J., Bowers W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation 2005, 2:23.
54. Jay T.R., Miller C.M., Cheng P.J., Graham L.C., Bemiller S., Broihier M.L., Xu G., Margevicius D., Karlo J.C., Sousa G.L., Cotleur A.C., Butovsky O., Bekris L., Staugaitis S.M., Leverenz J.B., Pimplikar S.W., Landreth G.E., Howell G.R., Ransohoff R.M., Lamb B.T. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 2015, 212:287-295.
55. Jenkins H.G., Bachelard H.S. Glycosaminoglycans in cortical autopsy samples from Alzheimer brain. J. Neurochem. 1988, 51:1641-1645.
56. Jin J.J., Kim H.D., Maxwell J.A., Li L., Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 2008, 5:23.
57. Junpee A., Tencomnao T., Sanprasert V., Nuchprayoon S. Association between Toll-like receptor 2 (TLR2) polymorphisms and asymptomatic bancroftian filariasis. Parasitol. Res. 2010, 107:807-816.
58. Kaisho T., Akira S. Toll-like receptor function and signaling. J. Allergy Clin. Immunol. 2006, 117:979-987. quiz 988.
59. Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J.: official publication of the Federation of American Societies for Experimental Biology 2002, 16:601-603.
60. Kankaanpaa J., Turunen S.P., Moilanen V., Horkko S., Remes A.M. Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer's disease. Neurobiol. Dis. 2009, 33:467-472.
61. Karch C.M., Goate A.M. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 2015, 77:43-51.
62. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol. Rev. 2011, 91:461-553.
63. Khariv V., Pang K., Servatius R.J., David B.T., Goodus M.T., Beck K.D., Heary R.F., Elkabes S. Toll-like receptor 9 deficiency impacts sensory and motor behaviors. Brain Behav. Immun. 2013, 32:164-172.
64. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004, 4:249-258.
65. Kong L., Ge B.X. MyD88-independent activation of a novel actin-Cdc42/Rac pathway is required for Toll-like receptor-stimulated phagocytosis. Cell Res. 2008, 18:745-755.
66. Kuo C.C., Liang S.M., Liang C.M. CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation. J. Biol. Chem. 2006, 281:38200-38207.
67. Kutikhin A.G. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum. Immunol. 2011, 72:1095-1116.
68. Landi F., Cesari M., Onder G., Russo A., Torre S., Bernabei R. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am. J. Geriatr. Psychiatry 2003, 11:179-185.
69. Lee E.Y., Yim J.J., Lee H.S., Lee Y.J., Lee E.B., Song Y.W. Dinucleotide repeat polymorphism in intron II of human Toll-like receptor 2 gene and susceptibility to rheumatoid arthritis. Int. J. Immunogenet. 2006, 33:211-215.
70. Lee Y.H., Bae S.C., Song G.G. Meta-analysis demonstrates association between TLR polymorphisms and rheumatoid arthritis. Genet. Mol. Res. 2013, 12:328-334.
71. Lehnardt S., Schott E., Trimbuch T., Laubisch D., Krueger C., Wulczyn G., Nitsch R., Weber J.R. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J. Neurosci. 2008, 28:2320-2331.
72. Letiembre M., Liu Y., Walter S., Hao W., Pfander T., Wrede A., Schulz-Schaeffer W., Fassbender K. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol. Aging 2009, 30:759-768.
73. Li X., Melief E., Postupna N., Montine K.S., Keene C.D., Montine T.J. Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Abeta42 phagocytosis. Am. J. Pathol. 2015, 185:230-239.
74. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
75. Liao W.L., Chen R.H., Lin H.J., Liu Y.H., Chen W.C., Tsai Y., Wan L., Tsai F.J. Toll-like receptor gene polymorphisms are associated with susceptibility to Graves' ophthalmopathy in Taiwan males. BMC Med. Genet. 2010, 11:154.
76. Lin H.Y., Tang C.H., Chen J.H., Chuang J.Y., Huang S.M., Tan T.W., Lai C.H., Lu D.Y. Peptidoglycan induces interleukin-6 expression through the TLR2 receptor, JNK, c-Jun, and AP-1 pathways in microglia. J. Cell Physiol. 2011, 226:1573-1582.
77. Lin H.Y., Tang C.H., Chen Y.H., Wei I.H., Chen J.H., Lai C.H., Lu D.Y. Peptidoglycan enhances proinflammatory cytokine expression through the TLR2 receptor, MyD88, phosphatidylinositol 3-kinase/AKT and NF-kappaB pathways in BV-2 microglia. Int. Immunopharmacol. 2010, 10:883-891.
78. Lin W., Ding M., Xue J., Leng W. The role of TLR2/JNK/NF-kappaB pathway in amyloid beta peptide-induced inflammatory response in mouse NG108-15 neural cells. Int. Immunopharmacol. 2013, 17:880-884.
79. Liu S., Liu Y., Hao W., Wolf L., Kiliaan A.J., Penke B., Rube C.E., Walter J., Heneka M.T., Hartmann T., Menger M.D., Fassbender K. TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J. Immunol. 2012, 188:1098-1107.
80. Lu C., Ha T., Wang X., Liu L., Zhang X., Kimbrough E.O., Sha Z., Guan M., Schweitzer J., Kalbfleisch J., Williams D., Li C. The TLR9 ligand, CpG-ODN, induces protection against cerebral ischemia/reperfusion injury via activation of PI3K/Akt signaling. J. Am. Heart Assoc. 2014, 3:e000629.
81. Lue L.F., Rydel R., Brigham E.F., Yang L.B., Hampel H., Murphy G.M., Brachova L., Yan S.D., Walker D.G., Shen Y., Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001, 35:72-79.
82. Maier M., Peng Y., Jiang L., Seabrook T.J., Carroll M.C., Lemere C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 2008, 28:6333-6341.
83. Mandrekar-Colucci S., Landreth G.E. Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord. Drug. Targets 2010, 9:156-167.
84. Marta M., Andersson A., Isaksson M., Kampe O., Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2008, 38:565-575.
85. Mazarati A., Maroso M., Iori V., Vezzani A., Carli M. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Exp. Neurol. 2011, 232:143-148.
86. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 1987, 79:195-200.
87. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
88. Michaud J.P., Halle M., Lampron A., Theriault P., Prefontaine P., Filali M., Tribout-Jover P., Lanteigne A.M., Jodoin R., Cluff C., Brichard V., Palmantier R., Pilorget A., Larocque D., Rivest S. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc. Nat. Acad. Sci. U.S.A. 2013, 110:1941-1946.
89. Minoretti P., Gazzaruso C., Vito C.D., Emanuele E., Bianchi M., Coen E., Reino M., Geroldi D. Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neurosci. Lett. 2006, 391:147-149.
90. Murr J., Carmichael P.H., Julien P., Laurin D. Plasma oxidized low-density lipoprotein levels and risk of Alzheimer's disease. Neurobiol. Aging 2014, 35:1833-1838.
91. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
92. Nischalke H.D., Coenen M., Berger C., Aldenhoff K., Muller T., Berg T., Kramer B., Korner C., Odenthal M., Schulze F., Grunhage F., Nattermann J., Sauerbruch T., Spengler U. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int. J. Cancer 2012, 130:1470-1475.
93. Noguchi E., Nishimura F., Fukai H., Kim J., Ichikawa K., Shibasaki M., Arinami T. An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin. Exp. Allergy 2004, 34:177-183.
94. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
95. Omar A.H., Yasunami M., Yamazaki A., Shibata H., Ofori M.F., Akanmori B.D., Shuaibu M.N., Kikuchi M., Hirayama K. Toll-like receptor 9 (TLR9) polymorphism associated with symptomatic malaria: a cohort study. Malar. J. 2012, 11:168.
96. Paresce D.M., Ghosh R.N., Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996, 17:553-565.
97. Paris D., Patel N., Quadros A., Linan M., Bakshi P., Ait-Ghezala G., Mullan M. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci. Lett. 2007, 415:11-16.
98. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., Choe K.H., Strassheim D., Pitts T.M., Tracey K.J., Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol. 2003, 284:C870-C879.
99. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., Sohn J.W., Yamada S., Maruyama I., Banerjee A., Ishizaka A., Abraham E. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 2006, 290:C917-C924.
100. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004, 279:7370-7377.
101. Perez N., Sugar J., Charya S., Johnson G., Merril C., Bierer L., Perl D., Haroutunian V., Wallace W. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res. Mol. Brain Res. 1991, 11:249-254.
102. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol. Aging 2001, 22:873-883.
103. Podlesniy P., Figueiro-Silva J., Llado A., Antonell A., Sanchez-Valle R., Alcolea D., Lleo A., Molinuevo J.L., Serra N., Trullas R. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann. Neurol. 2013, 74:655-668.
104. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., Piesche M., Schroers R., Weiss E., Kirschning C.J., Rochford C.D., Bruck W., Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Investig. 2006, 116:456-464.
105. Prohinar P., Rallabhandi P., Weiss J.P., Gioannini T.L. Expression of functional D299G.T399I polymorphic variant of TLR4 depends more on coexpression of MD-2 than does wild-type TLR4. J. Immunol. 2010, 184:4362-4367.
106. Qi Y., Zou L.B., Wang L.H., Jin G., Pan J.J., Chi T.Y., Ji X.F. Xanthoceraside inhibits pro-inflammatory cytokine expression in Abeta25-35/IFN-gamma-stimulated microglia through the TLR2 receptor, MyD88, nuclear factor-kappaB, and mitogen-activated protein kinase signaling pathways. J. Pharmacol. Sci. 2013, 122:305-317.
107. Rapic S., Backes H., Viel T., Kummer M.P., Monfared P., Neumaier B., Vollmar S., Hoehn M., Van der Linden A., Heneka M.T., Jacobs A.H. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:351-354.
108. Ravindran C., Cheng Y.C., Liang S.M. CpG-ODNs induces up-regulated expression of chemokine CCL9 in mouse macrophages and microglia. Cell Immunol. 2010, 260:113-118.
109. Reed-Geaghan E.G., Savage J.C., Hise A.G., Landreth G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A[beta]-stimulated microglial activation. J. Neurosci. 2009, 29:11982-11992.
110. Regen T., van Rossum D., Scheffel J., Kastriti M.E., Revelo N.H., Prinz M., Bruck W., Hanisch U.K. CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS. Brain Behav. Immun. 2011, 25:957-970.
111. Retz W., Gsell W., Munch G., Rosler M., Riederer P. Free radicals in Alzheimer's disease. J. Neural Transm. Suppl. 1998, 54:221-236.
112. Richard K.L., Filali M., Prefontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:5784-5793.
113. Rosenberger K., Dembny P., Derkow K., Engel O., Kruger C., Wolf S.A., Kettenmann H., Schott E., Meisel A., Lehnardt S. Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathway. Mol. Neurodegen. 2015, 10:5.
114. Saravanan P.B., Shanmuganathan M.V., Ramanathan M. Telmisartan attenuated LPS-induced neuroinflammation in human IMR-32 neuronal cell line via SARM in AT1R independent mechanism. Life Sci. 2015, 130:88-96.
115. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
116. Scholtzova H., Chianchiano P., Pan J., Sun Y., Goni F., Mehta P.D., Wisniewski T. Amyloid beta and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol. Commun. 2014, 2:101.
117. Scholtzova H., Kascsak R.J., Bates K.A., Boutajangout A., Kerr D.J., Meeker H.C., Mehta P.D., Spinner D.S., Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J. Neurosci. 2009, 29:1846-1854.
118. Song M., Jin J., Lim J.E., Kou J., Pattanayak A., Rehman J.A., Kim H.D., Tahara K., Lalonde R., Fukuchi K. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation 2011, 8:92.
119. Spitzer P., Herrmann M., Klafki H.W., Smirnov A., Lewczuk P., Kornhuber J., Wiltfang J., Maler J.M. Phagocytosis and LPS alter the maturation state of beta-amyloid precursor protein and induce different Abeta peptide release signatures in human mononuclear phagocytes. J. Neuroinflammation 2010, 7:59.
120. Stalder M., Deller T., Staufenbiel M., Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging 2001, 22:427-434.
121. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
122. Styren S.D., Civin W.H., Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp. Neurol. 1990, 110:93-104.
123. Suh E.C., Jung Y.J., Kim Y.A., Park E.M., Lee S.J., Lee K.E. Knockout of Toll-like receptor 2 attenuates Abeta25-35-induced neurotoxicity in organotypic hippocampal slice cultures. Neurochem. Int. 2013, 63:818-825.
124. Suh H.S., Zhao M.L., Choi N., Belbin T.J., Brosnan C.F., Lee S.C. TLR3 and TLR4 are innate antiviral immune receptors in human microglia: role of IRF3 in modulating antiviral and inflammatory response in the CNS. Virology 2009, 392:246-259.
125. Suryadevara N.C., Neela V.S., Devalraju K.P., Jain S., SivaSai K.S., Valluri V.L., Jonnalagada S., Anandaraj M.P. Influence of Intron II microsatellite polymorphism in human toll-like receptor 2 gene in leprosy. Hum. Immunol. 2013, 74:1034-1040.
126. Szczepanik A.M., Rampe D., Ringheim G.E. Amyloid-beta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 2001, 77:304-317.
127. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
128. Takata K., Kitamura Y., Kakimura J., Shibagaki K., Tsuchiya D., Taniguchi T., Smith M.A., Perry G., Shimohama S. Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem. Biophys. Res. Commun. 2003, 301:699-703.
129. Takata K., Takada T., Ito A., Asai M., Tawa M., Saito Y., Ashihara E., Tomimoto H., Kitamura Y., Shimohama S. Microglial Amyloid-beta1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. Int. J. Alzheimer's Dis. 2012, 2012:685739.
130. Tang S.C., Lathia J.D., Selvaraj P.K., Jo D.G., Mughal M.R., Cheng A., Siler D.A., Markesbery W.R., Arumugam T.V., Mattson M.P. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 2008, 213:114-121.
131. Tao K., Fujii M., Tsukumo S., Maekawa Y., Kishihara K., Kimoto Y., Horiuchi T., Hisaeda H., Akira S., Kagami S., Yasutomo K. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann. Rheum. Dis. 2007, 66:905-909.
132. Tong L., Prieto G.A., Kramar E.A., Smith E.D., Cribbs D.H., Lynch G., Cotman C.W. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1beta via p38 mitogen-activated protein kinase. J. Neurosci. 2012, 32:17714-17724.
133. Turano E., Busetto G., Marconi S., Guzzo F., Farinazzo A., Commisso M., Bistaffa E., Angiari S., Musumeci S., Sotgiu S., Bonetti B. Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: implications for Alzheimer's disease. Neurobiol. Aging 2015, 36:1780-1791.
134. Udan M.L., Ajit D., Crouse N.R., Nichols M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 2008, 104:524-533.
135. Velez D.R., Wejse C., Stryjewski M.E., Abbate E., Hulme W.F., Myers J.L., Estevan R., Patillo S.G., Olesen R., Tacconelli A., Sirugo G., Gilbert J.R., Hamilton C.D., Scott W.K. Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum. Genet. 2010, 127:65-73.
136. Venneti S., Lopresti B.J., Wang G., Hamilton R.L., Mathis C.A., Klunk W.E., Apte U.M., Wiley C.A. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 2009, 30:1217-1226.
137. Versijpt J.J., Dumont F., Van Laere K.J., Decoo D., Santens P., Audenaert K., Achten E., Slegers G., Dierckx R.A., Korf J. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 2003, 50:39-47.
138. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
139. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schuffer W., Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol. Biochem. 2007, 20:947-956.
140. Wan G.X., Cao Y.W., Li W.Q., Li Y.C., Zhang W.J., Li F. Associations between TLR9 polymorphisms and cancer risk: evidence from an updated meta-analysis of 25,685 subjects. Asian Pac. J. Cancer Prev. 2014, 15:8279-8285.
141. Wang L.Z., Tian Y., Yu J.T., Chen W., Wu Z.C., Zhang Q., Zhang W., Tan L. Association between late-onset Alzheimer's disease and microsatellite polymorphisms in intron II of the human toll-like receptor 2 gene. Neurosci. Lett. 2011, 489:164-167.
142. Wang L.Z., Yu J.T., Miao D., Wu Z.C., Zong Y., Wen C.Q., Tan L. Genetic association of TLR4/11367 polymorphism with late-onset Alzheimer's disease in a Han Chinese population. Brain Res. 2011, 1381:202-207.
143. Wang Y.L., Tan M.S., Yu J.T., Zhang W., Hu N., Wang H.F., Jiang T., Tan L. Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer's disease in Han Chinese. J. Neuroinflammation 2013, 10:101.
144. Williams W.M., Torres S., Siedlak S.L., Castellani R.J., Perry G., Smith M.A., Zhu X. Antimicrobial peptide beta-defensin-1 expression is upregulated in Alzheimer's brain. J. neuroinflammation 2013, 10:127.
145. Wisniewski H.M., Wegiel J., Wang K.C., Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol. 1992, 84:117-127.
146. Wu H.M., Zhang L.F., Ding P.S., Liu Y.J., Wu X., Zhou J.N. Microglial activation mediates host neuronal survival induced by neural stem cells. J. Cell Mol. Med. 2014, 18:1300-1312.
147. Xia M.Q., Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol. 1999, 5:32-41.
148. Xia M.Q., Qin S.X., Wu L.J., Mackay C.R., Hyman B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 1998, 153:31-37.
149. Xiang Y., Yan H., Zhou J., Zhang Q., Hanley G., Caudle Y., LeSage G., Zhang X., Yin D. The role of toll-like receptor 9 in chronic stress-induced apoptosis in macrophage. PLoS ONE 2015, 10:e0123447.
150. Yamamoto M., Kiyota T., Walsh S.M., Liu J., Kipnis J., Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J. Immunol. 2008, 181:3877-3886.
151. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 1999, 154:927-936.
152. Yasuno F., Kosaka J., Ota M., Higuchi M., Ito H., Fujimura Y., Nozaki S., Takahashi S., Mizukami K., Asada T., Suhara T. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(1)(1)C]DAA1106. Psychiatry Res. 2012, 203:67-74.
153. Yim J.J., Ding L., Schaffer A.A., Park G.Y., Shim Y.S., Holland S.M. A microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene: functional implications and racial differences. FEMS Immunol. Med. Microbiol. 2004, 40:163-169.
154. Yim J.J., Kim H.J., Kwon O.J., Koh W.J. Association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and nontuberculous mycobacterial lung disease in a Korean population. Hum. Immunol. 2008, 69:572-576.
155. Yim J.J., Lee H.W., Lee H.S., Kim Y.W., Han S.K., Shim Y.S., Holland S.M. The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immun. 2006, 7:150-155.
156. Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., Wakuda T., Sugihara G., Takebayashi K., Suda S., Iwata Y., Ueki T., Tsuchiya K.J., Suzuki K., Nakamura K., Ouchi Y. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:343-351.
157. Yu H.L., Li X.Y., Zhou X., Yuan L.H., Ma W.W., Xi Y.D., Zhao X., Wu J., Xiao R. Beta amyloid peptide (25-35) leading to inflammation through Toll-like receptors and the anti-inflammatory effect of genistein in BV-2 cells. J. Mol. Neurosci. 2013, 51:771-778.
158. Yu J.T., Miao D., Cui W.Z., Ou J.R., Tian Y., Wu Z.C., Zhang W., Tan L. Common variants in toll-like receptor 4 confer susceptibility to Alzheimer's disease in a Han Chinese population. Curr. Alzheimer Res. 2012, 9:458-466.
159. Yu J.T., Mou S.M., Wang L.Z., Mao C.X., Tan L. Toll-like receptor 2-196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. J. Neuroinflammation 2011, 8:136.
160. Zaheer A., Zaheer S., Thangavel R., Wu Y., Sahu S.K., Yang B. Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Brain Res. 2008, 1208:192-203.
161. Zhan X., Jickling G.C., Ander B.P., Stamova B., Liu D., Kao P.F., Zelin M.A., Jin L.W., DeCarli C., Sharp F.R. Myelin basic protein associates with AbetaPP, Abeta1-42, and amyloid plaques in cortex of Alzheimer's disease brain. J. Alzheimer's Dis.: JAD 2015, 44:1213-1229.